Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/05/15 12:43:20」(JST)

wiki en

Ribbon diagram of canakinumab (blue) bound to IL-1β (yellow) from PDB entry 5bvp^[1]

Canakinumab (INN, trade name Ilaris, previously ACZ885)^[2] is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.^[3]

Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the U.S. Food and Drug Administration (FDA) on June 2009^[4] and by the European Medicines Agency in October 2009.^[5] CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.

Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial was completed in October 2009.^[6] Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease,^[7] gout and coronary artery disease. It is also in trials for Schizophrenia.^[8] In gout it may result in better outcomes than a low dose of a steroid but costs five thousand times more.^[9]

References

^ PubMed
^ Dhimolea, Eugen (2010). "Canakinumab". MAbs 2 (1): 3–13. doi:10.4161/mabs.2.1.10328. PMC 2828573. PMID 20065636.
^ Lachmann, HJ; Kone-Paut I; Kuemmerle-Deschner JB; et al. (4 June 2009). "Use of canakinumab in the cryopyrin-associated periodic syndrome". New Engl J Med 360 (23): 2416–25. doi:10.1056/NEJMoa0810787. PMID 19494217.
^ "New biological therapy Ilaris approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease" (Press release). Novartis. 18 June 2009. Retrieved 28 July 2009.
^ Wan, Yuet (29 October 2009). "Canakinumab (Ilaris) and rilonacept (Arcalyst) approved in EU for treatment of cryopyrin-associated periodic syndrome". National electronic Library for Medicines. Retrieved 14 April 2010.
^ "clinicaltrials.gov, Identifier NCT00784628: Safety, Tolerability and Efficacy of ACZ885 (Canakinumab) in Patients With Active Rheumatoid Arthritis". Retrieved 2010-08-21.
^ Yasothan U, Kar S (2008). "Therapies for COPD". Nat Rev Drug Discov 7 (4): 285. doi:10.1038/nrd2533.
^ https://www.neura.edu.au/research/projects/canakinumab-add-treatment-schizophrenia-cats-study
^ Sivera, F; Wechalekar, MD; Andrés, M; Buchbinder, R; Carmona, L (Sep 1, 2014). "Interleukin-1 inhibitors for acute gout.". The Cochrane database of systematic reviews 9: CD009993. doi:10.1002/14651858.CD009993.pub2. PMID 25177840.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. リウマチ性疾患における生物学的製剤の概要 overview of biologic agents in the rheumatic diseases
2. クリオピリン関連周期性発熱症候群および関連疾患 cryopyrin associated periodic syndromes and related disorders
3. 全身型若年性特発性関節炎：治療 systemic juvenile idiopathic arthritis treatment
4. 急性痛風の治療 treatment of acute gout
5. 全身型若年性特発性関節炎：経過、予後、および合併症 systemic juvenile idiopathic arthritis course prognosis and complications

English Journal

The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1β.

Rondeau JM1, Ramage P1, Zurini M1, Gram H1.
mAbs.MAbs.2015 Nov 2;7(6):1151-60. doi: 10.1080/19420862.2015.1081323. Epub 2015 Aug 18.
Interleukin-1β (IL-1β) plays a key role in autoinflammatory diseases, such as systemic juvenile idiopathic arthritis (sJIA) or cryopyrin-associated periodic syndrome (CAPS). Canakinumab, a human monoclonal anti-IL-1β antibody, was recently approved for human use under the brand name Ilaris®. Can
PMID 26284424

Biologic-Associated Infections in Pediatric Rheumatology.

Horneff G1.
Current rheumatology reports.Curr Rheumatol Rep.2015 Nov;17(11):66. doi: 10.1007/s11926-015-0542-z.
During the past 15 years, biologics for juvenile idiopathic arthritis (JIA) therapy has led to new options. However, despite the high effectiveness and safety profile of these agents, infections are of great concern. The risk for bacterial infections, which appears to be increased in JIA patients a
PMID 26385753

Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome (TRAPS).

La Torre F1, Muratore M2, Vitale A3, Moramarco F4, Quarta L2, Cantarini L3.
Rheumatology international.Rheumatol Int.2015 Nov;35(11):1943-7. doi: 10.1007/s00296-015-3305-2. Epub 2015 Jun 6.
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) is an autosomal dominantly inherited autoinflammatory disease caused by mutations in the TNFRSF1A gene. Treatment is aimed at preventing acute disease attacks, improving quality of life, and preventing long-term complications such a
PMID 26048626

Japanese Journal

Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan

YOKOTA Shumpei,NISHIKOMORI Ryuta,TAKADA Hidetoshi,KIKUCHI Masako,NOZAWA Tomo,KANETAKA Taichi,KIZAWA Toshitaka,MIYAMAE Takako,MORI Masaaki,HEIKE Toshio,HARA Toshiro,IMAGAWA Tomoyuki
Modern rheumatology 23(3), 425-429, 2013-05-01
NAID 10031175900

クライオパイリン関連周期性発熱症候群に対するヒト化抗IL-1βモノクローナル抗体製剤カナキヌマブの効果

横田俊平,菊地雅子,野澤智,木澤敏毅,金高太一,宮前多佳子,森雅亮,西小森隆太,高田英俊,平家俊男,原寿郎,今川智之
日本臨床免疫学会会誌 = Japanese journal of clinical immunology 35(1), 23-29, 2012-02-28
… Canakinumab is a human IgG monoclonal antibody targeting IL-1β. … The clinical trials of canakinumab for patients with CAPS in both western countries and Japan were well-tolerated in most patients, and provided significant advantages over existing competitive therapies. … For us pediatrician, it will be important to be more careful for infectious diseases to provide the maximum safety of canakinumab for these patients. …
NAID 10030465541

海外の新薬審査情報を読み解く(新連載・第1回)カナキヌマブ(Canakinumab)

野村香織
月刊薬事 54(1), 103-105, 2012-01
NAID 40019150744

Related Pictures

Actualización en Inmunología 04-Oct-2013 Canakinumab: Interleukin-Inhibitor gegen Entzündungen ¿Sabe qué es el Canakinumab? Descúbrelo todo aquí Novartis (NVS) Updates On ACZ885 (Canakinumab) - CANTOS Study Results - Slideshow Mechanisms of actions of anakinra, canakinumab, gevokizumab, | Download Scientific El canakinumab (Ilaris) como tratamiento para la FMF | Afán por saber Ilaris - FDA prescribing information, side effects and uses European Commission Approves Canakinumab in SJIA

★リンクテーブル★

リンク元

「カナキヌマブ」

Canakinumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL-1β
Clinical data
Trade names	Ilaris
AHFS/Drugs.com	Consumer Drug Information
License data	EU EMA: Ilaris; US FDA: Canakinumab;
Routes of; administration	intravenous, subcutaneous
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	914613-48-2
ATC code	L04AC08 (WHO)
DrugBank	DB06168
ChemSpider	none
UNII	37CQ2C7X93
ChEMBL	CHEMBL1201834
Chemical data
Formula	C6452H9958N1722O2010S42
Molar mass	145.2 kg/mol
(what is this?) (verify)

　　[★]

英: canakinumab
商: イラリス

ヒトIL-1βに対する遺伝子組換えヒトIgG1モノクローナル抗体
ヒト型抗IL-1β抗体
CAPS治療薬

[1] PubMed

[2] Dhimolea, Eugen (2010). "Canakinumab". MAbs 2 (1): 3–13. doi:10.4161/mabs.2.1.10328. PMC 2828573. PMID 20065636.

[3] Lachmann, HJ; Kone-Paut I; Kuemmerle-Deschner JB; et al. (4 June 2009). "Use of canakinumab in the cryopyrin-associated periodic syndrome". New Engl J Med 360 (23): 2416–25. doi:10.1056/NEJMoa0810787. PMID 19494217.

[4] "New biological therapy Ilaris approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease" (Press release). Novartis. 18 June 2009. Retrieved 28 July 2009.

[5] Wan, Yuet (29 October 2009). "Canakinumab (Ilaris) and rilonacept (Arcalyst) approved in EU for treatment of cryopyrin-associated periodic syndrome". National electronic Library for Medicines. Retrieved 14 April 2010.

[6] "clinicaltrials.gov, Identifier NCT00784628: Safety, Tolerability and Efficacy of ACZ885 (Canakinumab) in Patients With Active Rheumatoid Arthritis". Retrieved 2010-08-21.

[7] Yasothan U, Kar S (2008). "Therapies for COPD". Nat Rev Drug Discov 7 (4): 285. doi:10.1038/nrd2533.

[8] ttps://www.neura.edu.au/research/projects/canakinumab-add-treatment-schizophrenia-cats-study

[9] Sivera, F; Wechalekar, MD; Andrés, M; Buchbinder, R; Carmona, L (Sep 1, 2014). "Interleukin-1 inhibitors for acute gout.". The Cochrane database of systematic reviews 9: CD009993. doi:10.1002/14651858.CD009993.pub2. PMID 25177840.

匿名

検索

案内

案内

canakinumab